Adverse event · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
1 finding from 1 review
Participants' global self‐assessment of acne improvement · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · participants with acne
Nicotinamide showed no clear difference in withdrawal for any reason (medium term: treatment duration from 5 to… compared with clindamycin (low certainty).
1 finding from 1 review
Minor adverse events · participants with acne
Nicotinamide showed no clear difference in total number of participants who experienced at least one minor… compared with clindamycin (low certainty).
1 finding from 1 review
Quality of life · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants' global self‐assessment of acne improvement · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · participants with acne
Nicotinamide showed no clear difference in withdrawal for any reason (medium term: treatment duration from 5 to… compared with erythromycin (low certainty).
1 finding from 1 review
Minor adverse events · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with acne
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
1 finding from 1 review
RR 0.71 [0.46, 1.1]
110 participants
Low
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review